S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
NASDAQ:TENX

Tenax Therapeutics (TENX) Stock Price, News & Analysis

$4.24
+0.37 (+9.56%)
(As of 03/28/2024 ET)
Today's Range
$3.86
$4.25
50-Day Range
$3.70
$14.26
52-Week Range
$3.48
$61.20
Volume
206,405 shs
Average Volume
154,986 shs
Market Capitalization
$1.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$480.00

Tenax Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
11,220.8% Upside
$480.00 Price Target
Short Interest
Healthy
2.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Tenax Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($28.80) to ($6.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.23 out of 5 stars

TENX stock logo

About Tenax Therapeutics Stock (NASDAQ:TENX)

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

TENX Stock Price History

TENX Stock News Headlines

Tenax Therapeutics: Q4 Earnings Insights
Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Former public company CEO now leads RTP firm
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
TENX: First Patient Enrolled
Why Is Tenax Therapeutics (TENX) Stock Down 64% Today?
TENX: IND Clears Way for Phase III
See More Headlines
Receive TENX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/16/2021
Today
3/29/2024
Next Earnings (Estimated)
4/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TENX
Employees
7
Year Founded
1967

Price Target and Rating

Average Stock Price Target
$480.00
High Stock Price Target
$480.00
Low Stock Price Target
$480.00
Potential Upside/Downside
+11,220.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-11,050,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$52.12 per share

Miscellaneous

Free Float
292,000
Market Cap
$1.27 million
Optionable
Not Optionable
Beta
2.29

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Christopher T. Giordano (Age 49)
    CEO, President & Director
    Comp: $442.12k
  • Dr. Stuart Rich M.D. (Age 74)
    Chief Medical Officer & Director
    Comp: $354.02k
  • Mr. Lawrence R. Hoffman CPA (Age 69)
    Esq., Interim Chief Financial Officer
  • Mr. Doug Randall
    Executive Vice President of Commercial & Business Operations
  • Dr. Douglas Hay
    Senior Vice President of Regulatory Affairs

TENX Stock Analysis - Frequently Asked Questions

Should I buy or sell Tenax Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tenax Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TENX shares.
View TENX analyst ratings
or view top-rated stocks.

What is Tenax Therapeutics' stock price target for 2024?

1 brokers have issued 1 year target prices for Tenax Therapeutics' shares. Their TENX share price targets range from $480.00 to $480.00. On average, they predict the company's stock price to reach $480.00 in the next year. This suggests a possible upside of 11,220.8% from the stock's current price.
View analysts price targets for TENX
or view top-rated stocks among Wall Street analysts.

How have TENX shares performed in 2024?

Tenax Therapeutics' stock was trading at $21.9680 at the start of the year. Since then, TENX stock has decreased by 80.7% and is now trading at $4.24.
View the best growth stocks for 2024 here
.

Are investors shorting Tenax Therapeutics?

Tenax Therapeutics saw a drop in short interest in March. As of March 15th, there was short interest totaling 36,700 shares, a drop of 49.4% from the February 29th total of 72,500 shares. Based on an average daily volume of 333,600 shares, the days-to-cover ratio is presently 0.1 days. Approximately 2.2% of the company's shares are short sold.
View Tenax Therapeutics' Short Interest
.

When is Tenax Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our TENX earnings forecast
.

How were Tenax Therapeutics' earnings last quarter?

Tenax Therapeutics, Inc. (NASDAQ:TENX) issued its earnings results on Tuesday, November, 16th. The specialty pharmaceutical company reported ($240.00) EPS for the quarter, missing analysts' consensus estimates of ($208.00) by $32.00.

When did Tenax Therapeutics' stock split?

Tenax Therapeutics shares reverse split on Wednesday, January 3rd 2024. The 1-80 reverse split was announced on Wednesday, January 3rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of Tenax Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tenax Therapeutics investors own include Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Idera Pharmaceuticals (IDRA), NVIDIA (NVDA), SCYNEXIS (SCYX), Verastem (VSTM), Bank of Hawaii (BOH), Gilead Sciences (GILD) and AVEO Pharmaceuticals (AVEO).

Who are Tenax Therapeutics' major shareholders?

Tenax Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (62.02%), Vanguard Group Inc. (62.43%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Tenax Therapeutics?

Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TENX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners